The Leading Community for Trusted Peptide Research & Insights
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.
Tirzepatide is a dual GIP/GLP-1 receptor agonist for weight management and type 2 diabetes. Marketed as Mounjaro (diabetes) and Zepbound (weight management). Outperforms semaglutide in head-to-head trials for both glucose control and weight loss.
Summary: Dual agonist that activates both GIP and GLP-1 receptors, producing synergistic effects on appetite suppression, insulin secretion, and energy metabolism. Mechanisms (reported/proposed across domains): Appetite & satiety • Activates GLP-1 receptors in the brain, suppressing appetite and increasing satiety signals. • GIP receptor activation may complement satiety effects (proposed),...
FDA Approved
Dose: 2.5–15 mg (titrated) · Route: Subcutaneous (SC) · Oral · Frequency: 1× weekly · Duration: 20–72+ weeks
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.